Amphastar P Stock Performance
| AMPH Stock | USD 22.51 0.12 0.53% |
The firm shows a Beta (market volatility) of 1.47, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Amphastar will likely underperform. At this point, Amphastar P has a negative expected return of -0.11%. Please make sure to confirm Amphastar's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Amphastar P performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Amphastar P has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders. ...more
Actual Historical Performance (%)
One Day Return (0.53) | Five Day Return 2.69 | Year To Date Return (38.09) | Ten Year Return 33.91 | All Time Return 157.26 |
1 | Earnings To Watch ANI Pharmaceuticals Reports Q1 Results Tomorrow | 05/08/2025 |
2 | Disposition of 273 shares by Peters William J of Amphastar at 24.79 subject to Rule 16b-3 | 05/19/2025 |
3 | Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference AMPH Stock News | 05/22/2025 |
4 | Acquisition by Zasloff Michael A of 11402 shares of Amphastar at 25.38 subject to Rule 16b-3 | 06/02/2025 |
5 | Disposition of 923 shares by Lee Howard of Amphastar at 26.01 subject to Rule 16b-3 | 06/03/2025 |
6 | Disposition of 200000 shares by Zhang Jack Y. of Amphastar at 13.03 subject to Rule 16b-3 | 06/13/2025 |
7 | Global Albuterol Market Forecast To Reach 6.29 Billion By 2029 With 7.1 percent Annual Growth | 06/16/2025 |
8 | U.S. Naloxone Market Projected To Witness Massive Growth, 2025-2032 Adapt Pharma, Mylan N.V., Hospira Inc | 06/25/2025 |
9 | Disposition of 500 shares by Petersen Floyd F. of Amphastar at 23.4679 subject to Rule 16b-3 | 07/02/2025 |
10 | Salbutamol Active Pharmaceutical Ingredient API Market Analysis 2025 Insights For Long-Term Investment Planning | 07/03/2025 |
11 | JPMorgan Downgrades Amphastar Pharmaceuticals to Neutral from Overweight, Brings PT Down to 30 | 07/10/2025 |
12 | Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters | 07/14/2025 |
13 | Amphastar Pharmaceuticals Inc Announces Major Expansion of U.S. ... | 07/15/2025 |
14 | Amphastar Pharmaceuticals Inc Shares Gap Down to 20.98 on Jul 18 | 07/18/2025 |
15 | Amphastar Pharmaceuticals earnings and shareholder returns have been trending downwards for the last year, but the stock lifts 6.4 percent this past week | 07/24/2025 |
| Begin Period Cash Flow | 144.5 M | |
| Total Cashflows From Investing Activities | -124.9 M |
Amphastar | Build AI portfolio with Amphastar Stock |
Amphastar Relative Risk vs. Return Landscape
If you would invest 2,441 in Amphastar P on April 26, 2025 and sell it today you would lose (190.00) from holding Amphastar P or give up 7.78% of portfolio value over 90 days. Amphastar P is currently does not generate positive expected returns and assumes 2.2576% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Amphastar, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amphastar Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amphastar's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amphastar P, and traders can use it to determine the average amount a Amphastar's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0477
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AMPH |
Estimated Market Risk
| 2.26 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Amphastar is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amphastar by adding Amphastar to a well-diversified portfolio.
Amphastar Fundamentals Growth
Amphastar Stock prices reflect investors' perceptions of the future prospects and financial health of Amphastar, and Amphastar fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amphastar Stock performance.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.076 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 1.48 B | ||||
| Shares Outstanding | 47.14 M | ||||
| Price To Earning | 972.67 X | ||||
| Price To Book | 1.42 X | ||||
| Price To Sales | 1.46 X | ||||
| Revenue | 712.81 M | ||||
| Gross Profit | 369.01 M | ||||
| EBITDA | 277.31 M | ||||
| Net Income | 159.52 M | ||||
| Cash And Equivalents | 183.39 M | ||||
| Cash Per Share | 3.74 X | ||||
| Total Debt | 650.55 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 3.64 X | ||||
| Book Value Per Share | 15.76 X | ||||
| Cash Flow From Operations | 213.39 M | ||||
| Earnings Per Share | 2.76 X | ||||
| Market Capitalization | 1.07 B | ||||
| Total Asset | 1.58 B | ||||
| Retained Earnings | 568.79 M | ||||
| Working Capital | 360.31 M | ||||
| Current Asset | 175.93 M | ||||
| Current Liabilities | 59.95 M | ||||
About Amphastar Performance
By evaluating Amphastar's fundamental ratios, stakeholders can gain valuable insights into Amphastar's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Amphastar has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amphastar has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 165.55 | 180.81 | |
| Return On Tangible Assets | 0.16 | 0.17 | |
| Return On Capital Employed | 0.15 | 0.15 | |
| Return On Assets | 0.10 | 0.11 | |
| Return On Equity | 0.22 | 0.23 |
Things to note about Amphastar P performance evaluation
Checking the ongoing alerts about Amphastar for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amphastar P help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amphastar P generated a negative expected return over the last 90 days | |
| About 73.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Amphastar Pharmaceuticals earnings and shareholder returns have been trending downwards for the last year, but the stock lifts 6.4 percent this past week |
- Analyzing Amphastar's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amphastar's stock is overvalued or undervalued compared to its peers.
- Examining Amphastar's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amphastar's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amphastar's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amphastar's stock. These opinions can provide insight into Amphastar's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Amphastar Stock analysis
When running Amphastar's price analysis, check to measure Amphastar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amphastar is operating at the current time. Most of Amphastar's value examination focuses on studying past and present price action to predict the probability of Amphastar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amphastar's price. Additionally, you may evaluate how the addition of Amphastar to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |